Innovation

Development Pipeline

Development Pipeline

We are determined to drive breakthrough innovations for patients in diseases of high unmet medical need. In clinical development we are currently advancing more than 30 projects that we review regularly so that we can give priority to the most promising programs.

Pipeline Overview

The following table lists a selection of major Pharma portfolio projects that we are advancing through different stages of development.

 

More detailed information on individual programs, therapeutic areas, and development timelines as well as a one-page overview of our development portfolio can be found in our overview package for download.

 

Uebersichtsgrafik-der-Phasen-08-02

Number of programs in clinical development.

 

Dr. Julia Schulze
R&D and Science - Research
Phase Area Program (Mode-of-action) Indication  
III ONC Copanlisib (PI3K Inhibitor) Non-Hodgkin Lymphoma Small Molecule
III ONC Darolutamide (AR Inhibitor) Prostate Cancer (mHSPC) Small Molecule
III ONC Darolutamide (AR Inhibitor) Adjuvant Prostate Cancer Small Molecule
III CVD Finerenone (MR Antagonist) Heart Failure (HFmr/pEF) Small Molecule
III CVD Finerenone (MR Antagonist) Non-diabetic CKD Small Molecule
III CVD Vericiguat (sGC Stimulator) Heart Failure (HFrEF) Small Molecule
III CVD Asundexian (FXIa Inhibitor) Stroke Prevention in Atrial Fibrillation
Insight Story Link
Small Molecule
III CVD Asundexian (FXIa Inhibitor) 2 Stroke Prevention (OCEANIC Stroke)
Small Molecule
III WH Elinzanetant (Neurokinin-1,3 Rec Antag.) Vasomotor Symptoms Small Molecule
II ONC Regorafenib (combi Nivolumab) Solid tumors (recurrent or metastatic) Small Molecule
II CVD Asundexian (FXIa Inhibitor) Major Adverse Cardiac Events Prevention
Insight Story Link
Small Molecule
II CVD Runcaciguat (sGC Activator) Chronic Kidney Disease (CKD) Small Molecule
II Other Runcaciguat (sGC Activator) Non-prolif. Diabetic Retinopathy (NPDR) Small Molecule
II Other BDKRB1 Receptor Antagonist Neuropathic Pain Small Molecule
II Other Gadoquatrane (High Relaxivity Contrast Agent) Magnetic Resonance Imaging (HRCA-PAT) Contrast Agent_NTE
II Other Adrenomedullin Pegol (PEG-ADM) Acute Resp. Distress Syn. (ARDS) Biologic_NTE
II Other Zabedosertib (IRAK4 Inhibitor) Atopic Dermatitis (DAMASK) Small Molecule
I ONC Elimusertib (ATR Inhibitor) Advanced solid tumors, Non-Hodgkin's
Lymphoma, Mantle Cell Lymphoma
Small_Molecule_NTE
I ONC AhR Inhibitor Advanced solid tumors
Insight Story Link
Small_Molecule_NTE
I ONC mEGFR Inhibitor Advanced Non-small Cell Lung Cancer with
EGFR Mutation and/or HER2 Mutation
Small_Molecule_NTE
I ONC DGKzeta Inhibitor Cancer Small_Molecule_NTE
I ONC CCR8 Ab Advanced solid tumors Antibody
I CVD Congestive Heart Failure Gene Therapy Congestive Heart Failure Gene Therapy_NTE
I CVD sGC Activator Chronic Kidney Disease Small_Molecule_NTE
I CVD Anti-a2AP Acute Ischemic Stroke;
Pulmonary Embolism
Antibody
I WH P2X4 Antagonist Endometriosis Small_Molecule_NTE
I WH BDKRB1 Receptor Antagonist Endometriosis Small_Molecule_NTE
I Other sGC Activator Acute Respiratory Distress Syndrome Small_Molecule_NTE
I Other Bemdaneprocel
(Parkinson’s Disease Cell Therapy)
Parkinson's Disease Cell Therapy_NTE
I Other Parkinson‘s Disease Gene Therapy Parkinson's Disease Gene Therapy_NTE
I Other Multiple System Atrophy Gene Therapy Multiple System Atrophy Gene Therapy_NTE
I Other Pompe Disease Gene Therapy Pompe Disease Gene Therapy_NTE
I Other Huntington‘s Disease Gene Therapy   Gene Therapy_NTE
I Other GPR84 Antagonist   Small_Molecule_NTE
0* ONC DGKalpha Inhibitor Cancer Small_Molecule_NTE
0* ONC PSMA TAC Advanced Prostate Cancer Radiotherapy_NTE
0* ONC PSMA SMOL TAC Advanced Prostate Cancer Radiotherapy_NTE
0* ONC VVD NRF2 Inhibitor Cancer Small_Molecule_NTE
0* ONC VVD STAT3 Inhibitor Cancer Small_Molecule_NTE
0* CVD SEMA 3a Alport Syndrome Antibody
0* Other LGMD2i Gene Therapy Limb-Girdle Muscular Dystrophy 2i Gene Therapy_NTE
0* Other Next Generation Liver MRI Contrast Media Contrast Agent_NTE

* Pre-clinical selected assets on path to IND

Legende_pipeline

 

New Molecular Entity New molecular entity
Life cycle management Life cycle management

 

Pamela Cohen
Pamela Cohen
R&D and Science - Development